Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Moleculin Biotech announced that its pivotal MIRACLE trial for Annamycin in relapsed/refractory AML has enrolled its 45th subject. This milestone triggers the final phase of preparation for the interim data unblinding, which remains on track for mid-2026.
Key figures
- Drug Name
- Annamycin (naxtarubicin)
- Phase Of Trial
- Phase 2B/3
- Trial name
- MIRACLE
- Subjects enrolled
- 45
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.